Zobrazeno 1 - 10
of 71
pro vyhledávání: ''
Autor:
Martin Schuler, Till Ploenes, Martin Metzenmacher, Clemens Aigner, Smiths S Lueong, Balazs Hegedus, Dirk Theegarten, Peter A. Horn, Jens T. Siveke, Hans-Ulrich Schildhaus, Jan Forster, Christoph Klein, Nicola Bielefeld, Alexander Schramm
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101279-(2022)
Translational Oncology
Translational Oncology
Highlights • High concordance rate in variant calls from tumor biopsies and the corresponding liquid biopsy-derived DNA sample. • ctDNA sequencing allows for unbiased characterization of molecular tumor architecture and reveal the presence of oth
Autor:
Annamaria Colao, Barbara Altieri, Ylenia Capodanno, Joerg Schrader, Antongiulio Faggiano, Richard Elders
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101269-(2022)
Translational Oncology
Translational Oncology
Highlights • Major challenges are still faced in the treatment of human malignant insulinoma. • None of the available insulinoma models represent faithfully the malignant disease. • Canine insulinoma has an incidence of malignancy of 95% and a
Autor:
Nicolas Santoyo, Luis Corrales, Andrés F. Cardona, Luis Mas, Suraj Samtani, Feliciano Barrón, Jorge Otero, L. Rojas, Claudio Martin, Christian Rolfo, Rafael Rosell, Camila Ordoñez, C. Sotelo, Oscar Arrieta, CLICaP, Hernán Carranza, July Rodriguez, Luisa Ricaurte, Carlos Vargas, D. Mayorga, Alessandro Russo, Maritza Bermudez, Alejandro Ruiz-Patiño, Pilar Archila, Lucia Zatarain-Barrón, Juan Esteban Garcia-Robledo, ONCOLGroup, Tatiana Gamez, J. Ávila, Gonzalo Recondo, Umberto Malapelle
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101276-(2022)
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Translational Oncology
Repositorio U. El Bosque
Universidad El Bosque
instacron:Universidad El Bosque
Translational Oncology
Highlights • The identification of the KRAS G12C mutation in non-small cell lung cancer is relevant with new molecules being introduced for treatment. • The variation of mutation prevalence among different regions indicate that certain population
Publikováno v:
Translational Oncology, Vol 15, Iss 1, Pp 101268-(2022)
Translational Oncology
Translational Oncology
Highlights • Pre-treatment prognostic score based on clinical stage, ECOG PS, LDH, Alb and PLR may help to identify aNSCLC patients who may benefit from immune checkpoint inhibitors (ICIs). • Among patients with PD-L1 expression ≥ 50%, pre-trea
Publikováno v:
Translational Oncology, Vol 14, Iss 12, Pp 101222-(2021)
Translational Oncology
Translational Oncology
Highlights • A transcriptomic, biological pathway-based machine learning model was constructed. • This classification model can predict LCNEC from borderline samples. • The model may help clinicians choose appropriate therapy for pulmonary NETs
Publikováno v:
Translational Oncology, Vol 14, Iss 12, Pp 101225-(2021)
Translational Oncology
Translational Oncology
Highlight • This study conducted a battery of bioinformation analysis to calculate novel prognostic markers based on metabolism-related DEGs and verified the new prognostic index on the basis of the prognostic models. • We use a series of algorit
Autor:
Lixin Su, Liming Zhang, Deming Wang, Tong Xia, Xindong Fan, Xiao Li, Xunjie Shang, Xiao-yan Li, Xitao Yang, Yuchen Shen
Publikováno v:
Translational Oncology, Vol 14, Iss 12, Pp 101233-(2021)
Translational Oncology
Translational Oncology
Highlights • Pyroptosis genes were differentially expressed between HNSCC and normal tissue. • Developed a model for prognostic prediction of HNSCC based on pyroptosis genes. • The risk-score model was proved to be promising and reliable in pra
Autor:
Francesco Perri, Francesco Caponigro, Carmine De Angelis, Alessandro Ottaiano, Gerardo Botti, Giuseppina Della Vittoria Scarpati, Francesco Longo, Franco Ionna
Publikováno v:
Translational Oncology, Vol 13, Iss 2, Pp 262-274 (2020)
Translational Oncology
Translational Oncology
Head and neck carcinoma (HNC) are diseases arising from several tracts of the aerodigestive ways. Most HNC are squamous cell carcinoma (SCCHN). Immunotherapy is a treatment strategy aimed to reinforce the immune system. Several types of immunotherapy
Autor:
Dong-Hua Luo, Qun Zhang, Feng Jiang, Wei-Min Mao, Xiaozhong Chen, Yuan-Yuan Chen, Ting Jin, Qi-Feng Jin
Publikováno v:
Translational Oncology, Vol 13, Iss 1, Pp 25-31 (2020)
Translational Oncology
Translational Oncology
PURPOSE: In contrast to other studies, our previous study showed that adding induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) significantly worsened the prognosis of patients with stage II nasopharyngeal carcinoma (NPC). However, th
Autor:
Hans Wildiers, Cécile Reyes, Sileny Han, Lorenza Mittempergher, Timothé Cynober, F Reyal, Leonie J. M. J. Delahaye, Kevin Punie, Liesbet Vliegen, Ines Nevelsteen, Enora Laas Faron, Laurence Slembrouck, Petra Sintubin, Sara Vander Borght, G Hoste, Patrick Neven, Giuseppe Floris, Audrey Rapinat, Ann Smeets, Sylvain Baulande, Lynn Jongen, Mylène Bohec, Virginie Raynal, David Gentien, Céline Helsmoortel, Mireille Snel, Els Van Nieuwenhuysen, Lauren Darrigues, Isabelle Vanden Bempt, Anke T. Witteveen, Sari Neijenhuis, Cecile Laurent, Annuska M. Glas, Anne Vincent Salomon
Publikováno v:
Translational Oncology, Vol 12, Iss 12, Pp 1557-1565 (2019)
Translational Oncology
Translational Oncology
A previously developed and centrally validated MammaPrint® (MP) and BluePrint® (BP) targeted RNA next-generation sequencing (NGS) kit was implemented and validated in two large academic European hospitals. Additionally, breast cancer molecular subt